Presentation_of_the_BAA_Webinar.pdf

PDF 332 KB Posted

Attached to
ACCELERATOR TO END TB IN INDIA
Solicitation number
BAA-ROAA-ENDTB-2019
Issued by

About this file

Webinar Presentation

View the file

Other files

File Type Posted
Amendment_05_to_BAA-ROAA-ENDTB-2019.pdf PDF
Amend_No._4_-_BAA.pdf PDF
Amendment_No._3_-_BAA.pdf PDF
BAA_-_TB_Announcement.pdf PDF

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT

American Embassy Chanakyapuri New Delhi 110 021 Tel: 91-11-24198000 Fax: 91-11-24198612 www.usaid.gov/in

SUBJECT: BROAD AGENCY ANNOUNCEMENT (BAA) NO. BAA-ROAA-ENDTB-2019

AMENDMENT NO. 3

PROJECT NAME: ACCELERATOR TO END TUBERCULOSIS IN INDIA

Dear Applicants, Amendment No. 3 to the subject BAA is issued to post the Webinar Presentation. The Webinar was conducted on April 22, 2019.

Refer to the following pages for viewing the presentation.

4/23/2019 USAID /India Health Office 1

Introducing the Broad Agency Announcement for the Accelerator to End TB in India Introducing the Broad Agency Announcement for the Accelerator to End TB in India

The USAID India Health Office The USAID India Health Office

A

FP

4:00 - 4:05 pm Regional Office of Acquisition and Assistance (ROAA) and Health Office welcome

4:05 - 4:25 pm Presentation

4: 25 - 5:55 pm Question and answers facilitated by ROAA

5:55 - 6:00 pm Closing remarks by ROAA

4/23/2019 USAID /India Health Office 2

Agenda

4/23/2019 USAID/India Health Office 3

The Problem Statement

Gaps

Preventing

TB

Early and Accurate Diagnosis

Successful Treatment Outcomes

Non-medicalized Response to

TB Care

4/23/2019 USAID/India Health Office 4

Service delivery platforms to deliver high-quality person-centered TB and MDR/RR-

TB services

Community-led, person-centered prevention, care and support models

Research objective: To rapidly demonstrate and rigorously test human-centered, high-impact and novel solutions that can accelerate the GOI’s efforts to eliminate TB by 2025

CREATE AN ENABLING ENVIRONMENT

USE INNOVATIVE FINANCING

DEPLOY EFFECTIVE DIGITAL TECHNOLOGY

Accelerator to End TB (including MDR/RR- TB) in India

Strengthening service delivery platforms to deliver high-quality patient-centered TB and MDR/RR-TB services by:

• Maximizing the impact of quality prevention, diagnostic and treatment services

• Working in both public and private facilities across all cadres of personnel

• Ensuring the right knowledge, skills and attitudes, in the right places with the right motivation

• Modeling differentiated patient-centric care using strategies and approaches generated through state-of-the-art tools and evidence

Demonstrating community-led, person-centered prevention, care and support models by:

• Testing models where communities and families are instrumental in delivering differentiated care for populations that may have unique challenges accessing services

• Designing custom made services tailored to the needs of vulnerable people such as those with MDR/RR-TB, children, people living with HIV, diabetics, tobacco users and alcohol dependents, and more

• Enabling women to overcome stigma, discrimination and other barriers in accessing TB services

• Measuring the impact of community-based activities and associated costs to the patient and the health system

4/23/2019 USAID/India Health Office 5

The Pillars

Create an enabling environment

• Propose evidence- based solutions to address bottlenecks that hinder an enabling environment

• Take a holistic approach to the needs and environment of people affected by TB including MRD/RR-TB

• Focus on positive interventions that do not further stigmatize or prevent access

• Acknowledge the importance of positive, inclusive language

• Put the patient at the center of action

Use innovative financing approaches

• Identify innovative solutions for patient side and facility side financing challenges

• Propose effective approaches to reduce the financial burden on individuals and families affected with TB

• Identify financing approaches that can improve institutions’ ability to cost-effectively bring state-of-the-art diagnosis, treatment and care to those affected by TB, while focusing more on results and outcomes

4/23/2019

USAID/India Health Office

Cross-cutting areas Deploy effective digital technologies to amplify impact

• Solve gaps across any part of the prevention, care and treatment cascade (i.e. the patient, frontline workers, labs, physicians, etc.)

• Address concerns around care seeking, screening, diagnostic and notification, treatment initiation, and adherence and treatment support

• Explore solutions beyond the initial innovation stage, and have some degree of market readiness are preferred

• Provide access in rural and remote areas with limited connectivity and electricity

W ha t w e ar e lo ok in g fo r • Evidence-based ideas, including creativity of the given approach and clear differentiation from existing approaches

• Cost-conscious and adaptable for Indian settings, particularly at the sub-national level

• Ability to be scaled rapidly and cost effectively in an Indian context

• Strong likelihood of achieving a substantial impact

• Ability to make significant improvements within the first year of demonstration

W e ar e

N O

T lo ok in g fo r • Research that does not provide a clear path to development and testing of intervention strategies

• Solutions that are less efficacious than current technologies or approaches

• Proven approaches that are already in use in the field

• Basic research, clinical trials or laboratory-intensive research

• Discovery science, capacity-building-only initiatives, ongoing programmatic funding or infrastructure development

4/23/2019 USAID/India Health Office 7

STAGE 1

SUBMISSION OF

EXPRESSIONS OF

INTEREST (EOIS)

STAGE 2

CO-CREATION

AND CO-

DEVELOPMENT OF

THE CONCEPT

PAPER

STAGE 3

REVIEW BY THE

PEER AND

SCIENTIFIC

REVIEW BOARD

STAGE 4

AWARD

DETERMINATION

4/23/2019 USAID/India Health Office 8

The BAA Process

A. Be In English, no more than 2 pages in length, and no smaller than 12 point font;

B. Be submitted electronically to indiarco@usaid.gov;

C. Contain a header with the following information (included in the page count):

a. Respondent Name/Group and Contact Information;

b. Response Title;

c. BAA Addendum Name/Number;

d. Optional graphic that fits on an 8.5”x11” or A4 piece of paper (included in the page limit);

D. Be in .pdf, .docx, or .odf format

4/23/2019 USAID/India Health Office 9

All EOI’s must

4/23/2019 10

For more information please contact indiarco@usaid.gov For more information please contact indiarco@usaid.gov

File details come from the government source that posted it.